TRACON Pharmaceuticals, Inc. Appoints Scott B. Brown as Chief Financial Officer
February 02, 2021 at 04:39 pm EST
Share
On January 29, 2021, the board of directors of TRACON Pharmaceuticals, Inc. (the “Company”) appointed Scott B. Brown, CPA, M.S. as Chief Financial Officer of the Company. Mr. Brown was also appointed as the Company’s principal financial officer, replacing Charles P. Theuer, M.D., Ph.D. in that role. Mr. Brown, age 40, has served as the Company’s Chief Accounting Officer and Head of Finance since September 2019. Mr. Brown previously served as the Company’s Vice President, Finance from January 2019 to September 2019, the Company’s Sr. Director, Finance and Controller from January 2017 to January 2019 and the Company’s Director, Finance and Controller from August 2015 to January 2017.
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Companyâs clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.
TRACON PHARMACEUTICALS, INC. 
